Johannesburg - Ascendis Health, which just wrapped up major deals, says transaction costs have impacted its results for the year to June.
The listed company says headline earnings per share are 30 percent lower at 56c a share, while normalised headline earnings per share - stripping out these once off costs - came in at 121c a share, a 30 percent gain.
It declared a total dividend of 21.5c a share, a 13 percent gain.
Ascendis Health, home to Pharma-Med, Consumer Brands and Phyto-Vet, last month completed its R7.3 billion purchase of Cyprus-based Pharmaceutical manufacturer Remedica, and Europe-based sports nutrition company Scitec.
It says in its results it is increasingly focused on international growth from its base in South Africa and completed its first offshore acquisition in July 2015 with the purchase of an initial 49 percent stake in Spanish pharma business Farmalider.
Read also: Ascendis wraps up R7.3bn in deals
During the year, revenue increased 39 percent to R3.9 billion, driven by organic growth of 9 percent and supported by growth of 30 percent from acquisitions concluded over the past year.
The acquisitive growth of R626 million includes revenue from Farmalider in Spain (consolidated for eleven months) and Akacia Healthcare (consolidated for three months) as well as smaller bolt-on acquisitions across all segments.
It says its profitability and earnings for the 12 months were impacted by transaction costs of R143 million relating to Remedica and Scitec. The earnings from these acquisitions will only be included from August 2016, which it says results in a misalignment of the costs and earnings relating to these acquisitions which has had a negative impact on reported earnings for the current reporting period.
IOL